Lycera Announces Presentations of Positive Preclinical Results for Lead Candidate LYC-30937 and for Selective Rho kinase Inhibitor Program at the 11th Congress of the European Crohn's and Colitis Organization (ECCO)
![Galapagos Reports Positive Phase 2 Trial Data of Crohn's Disease Drug Filgotinib at ECCO Congress - IBD News Today Galapagos Reports Positive Phase 2 Trial Data of Crohn's Disease Drug Filgotinib at ECCO Congress - IBD News Today](https://ibdnewstoday.com/wp-content/uploads/2016/03/shutterstock_392092564-375x475@2x.jpg)
Galapagos Reports Positive Phase 2 Trial Data of Crohn's Disease Drug Filgotinib at ECCO Congress - IBD News Today
![ECCO 2017: European Cancer Congress - The voice of multidisciplinary cancer care in Europe | HealthManagement.org ECCO 2017: European Cancer Congress - The voice of multidisciplinary cancer care in Europe | HealthManagement.org](https://res.cloudinary.com/healthmanagement-org/image/upload/f_auto,fl_lossy/v1469607607/cw/00108183_cw_image.jpg)